We are live on ! Find out more
BXRX

Baudax Bio, Inc. Common Stock
BXRX

Delisted

BXRX was delisted on the 15th of November, 2023.

Back to rankings

31 hedge funds and large institutions have $9.43M invested in Baudax Bio, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

756% more call options, than puts

Call options by funds: $899K | Put options by funds: $105K

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

49% more capital invested

Capital invested by funds: $6.34M → $9.43M (+$3.09M)

9% less funds holding

Funds holding: 34 → 31 (-3)

23% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 13

Holders
31
Holders Change
-3
Holders Change %
-8.82%
% of All Funds
0.54%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
9
Reduced
4
Closed
13
Calls
$899K
Puts
$105K
Net Calls
+$794K
Net Calls Change
+$734K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$4.85M
2
BlackRock
BlackRock
New York
+$1.82M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$482K
4
Two Sigma Advisers
Two Sigma Advisers
New York
+$190K
5
Northern Trust
Northern Trust
Illinois
+$150K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$3.54M
2
Renaissance Technologies
Renaissance Technologies
New York
-$426K
3
GCP
GSA Capital Partners
United Kingdom
-$290K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$256K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$134K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$5.02M +$4.85M +2,426 +685%
BlackRock
2
BlackRock
New York
$1.86M +$1.82M +909 +733%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$527K +$482K +241 +463%
Two Sigma Investments
4
Two Sigma Investments
New York
$294K +$144K +72 +79%
BGIM
5
Brandywine Global Investment Management
Pennsylvania
$282K -$4K -2 -1%
Two Sigma Advisers
6
Two Sigma Advisers
New York
$239K +$190K +95 +250%
Northern Trust
7
Northern Trust
Illinois
$220K +$150K +75 +160%
Citadel Advisors
8
Citadel Advisors
Florida
$169K +$22K +11 +13%
Bank of New York Mellon
9
Bank of New York Mellon
New York
$131K +$144K +72 New
IC
10
Ikarian Capital
Texas
$129K – – –
EDRH
11
Edmond de Rothschild Holding
Switzerland
$129K +$142K +71 New
Osaic Holdings
12
Osaic Holdings
Arizona
$74K +$8K +4 +11%
MML Investors Services
13
MML Investors Services
Massachusetts
$58K +$64K +32 New
Charles Schwab
14
Charles Schwab
California
$45K +$48K +24 New
California Public Employees Retirement System
15
California Public Employees Retirement System
California
$35K – – –
Commonwealth Equity Services
16
Commonwealth Equity Services
Massachusetts
$29K – – –
Millennium Management
17
Millennium Management
New York
$26K – – –
GCP
18
GSA Capital Partners
United Kingdom
$24K -$290K -145 -92%
LPL Financial
19
LPL Financial
California
$22K +$24K +12 New
SIP
20
Stoneridge Investment Partners
Pennsylvania
$19K – – –
BFM
21
Boothbay Fund Management
New York
$18K – – –
Victory Capital Management
22
Victory Capital Management
Texas
$15K +$16K +8 New
OC
23
Oppenheimer & Co
New York
$15K +$18K +9 New
UBS Group
24
UBS Group
Switzerland
$14K +$16K +8 New
GLA
25
Good Life Advisors
Pennsylvania
$13K +$14K +7 New
1
2

BXRX Hedge Fund Activity: Q1 2021 in Review

31 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q1 2021, worth a combined $9.43M — up 49% from $6.34M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of BXRX and 10 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 9 added.

The largest buyer was Vanguard Group, adding an estimated $4.85M. The largest seller was Armistice Capital, exiting entirely with an estimated $3.54M sold.

  • 31 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q1 2021, down from 34 in Q4 2020.
  • Funds reported $9.43M of Baudax Bio, Inc. Common Stock stock for Q1 2021, up 49% quarter-over-quarter.
  • 10 funds opened new Baudax Bio, Inc. Common Stock positions in Q1 2021 and 13 closed out, a net change of -3 holders.
  • The largest Baudax Bio, Inc. Common Stock buyer in Q1 2021 was Vanguard Group, an estimated $4.85M added.
  • The largest Baudax Bio, Inc. Common Stock seller in Q1 2021 was Armistice Capital, an estimated $3.54M sold.

Based on aggregated 13F filings for Q1 2021.